Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant tissue plasminogen activator

S G Bell

    Neonatal Network : NN
    |September 1, 1996
    PubMed
    Summary
    This summary is machine-generated.

    Recombinant tissue plasminogen activator shows promise for treating clots in neonates with intravascular catheters. Further controlled studies are needed to confirm its safety and efficacy in this vulnerable population.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Management of secondary Paget's disease of the vulva associated with transitional cell carcinoma.

    Journal of cancer research and clinical oncology·2022
    Same author

    Structural information from orientationally selective DEER spectroscopy.

    Physical chemistry chemical physics : PCCP·2009
    Same author

    Histological findings of the internal inguinal ring in patients having indirect inguinal hernia.

    Hernia : the journal of hernias and abdominal wall surgery·2009
    Same author

    Sphincter-like motion following mechanical dilation of the internal inguinal ring during indirect inguinal hernia procedure.

    Hernia : the journal of hernias and abdominal wall surgery·2008
    Same author

    Engineering substrate recognition in catalysis by cytochrome P450cam.

    Biochemical Society transactions·2003
    Same author

    Engineering the CYP101 system for in vivo oxidation of unnatural substrates.

    Protein engineering·2001
    Same journal

    A Quality Improvement Project to Increase Breastfeeding Rates in the NICU.

    Neonatal network : NN·2026
    Same journal

    Parental Advocacy in the NICU: A Unique Case of Infant Hypoglycemia Highlighting the Role of the Family in Improving Outcomes.

    Neonatal network : NN·2026
    Same journal

    Enteral Iron Supplementation.

    Neonatal network : NN·2026
    Same journal

    Enjoyment in Preterm Infants: Exploring Clinical and Research Perspectives in the Neonatal Intensive Care Unit.

    Neonatal network : NN·2026
    Same journal

    Building the Future Neonatal Nurse Practitioner Workforce: Reviewing Barriers and Strategies to Enrollment.

    Neonatal network : NN·2026
    Same journal

    What Does It Mean to Be a Professional?

    Neonatal network : NN·2026
    See all related articles

    Area of Science:

    • Neonatal medicine
    • Vascular surgery
    • Pharmacology

    Background:

    • Indwelling intravascular catheters are widely used in neonates, leading to increased thrombotic complications.
    • Current thrombolytic therapies pose risks due to systemic fibrinolysis, particularly in premature infants.

    Purpose of the Study:

    • To evaluate the potential of recombinant tissue plasminogen activator (rt-PA) as a locally acting thrombolytic agent in neonates.
    • To address the need for safer and more effective clot lysis strategies in neonatal intensive care.

    Main Methods:

    • Literature review of existing reports on rt-PA use in neonatal populations.
    • Analysis of rt-PA's mechanism of action as a naturally occurring, locally acting enzyme.
    • Consideration of rt-PA production via recombinant DNA technology.

    Related Experiment Videos

    Main Results:

    • rt-PA appears promising for local lysis of clots associated with intravascular catheters in neonates.
    • Early reports suggest potential benefits in managing thrombotic complications without significant systemic effects.

    Conclusions:

    • Recombinant tissue plasminogen activator may offer a safer alternative for thrombolytic therapy in neonates.
    • Controlled clinical studies are essential to establish the efficacy and safety profile of rt-PA in this patient group.